Berbamine inhibits the growth of liver cancer cells and cancer-initiating cells by targeting Ca2+/calmodulin- dependent protein kinase II

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 2067-2077

  Meng, Zhipeng ^a   Li, Tao ^a   Ma, Xiaoxiao ^a   Wang, Xiaoqiong ^a,e   Ness, Carl Van ^a   Gan, Yichao ^c,d   Zhou, Hong ^c,d   Tang, Jinfen ^c,d   Lou, Guiyu ^a,b   Wang, Yafan ^a   Wu, Jun ^a   Yen, Yun ^a   Xu, Rongzhen ^c,d   Huang, Wendong ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLBENZOYL BERBAMINE; BBD 24; BERBAMINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; MOUSE; NOD SCID MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANIMALS; APOPTOSIS; BENZYLISOQUINOLINES; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885624465     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0314     Document Type: Article

References (35)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: Cancer J Clin 2012;62: 10-29.
2. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005;23: 2892-9.
3. Kassahun WT, Fangmann J, Harms J, Hauss J, Bartels M. Liver resection and transplantation in the management of hepatocellular carcinoma: a review. Exp Clin Transplant 2006;4: 549-58.
4. Carr BI. Some new approaches to the management of hepatocellular carcinoma. Semin Oncol 2012;39: 369-73.
5. Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Semin Oncol 2012;39: 486-92.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
7. Xin HW, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen JQ, et al. Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut. 2013 Feb 14. [Epub ahead of print].
8. Mishra BB, Tiwari VK. Natural products: an evolving role in future drug discovery. Eur J Med Chem 2011;46: 4769-807.
9. Schumacher M, Kelkel M, Dicato M, Diederich M. A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2010. Molecules 2011;16: 5629-46.
10. Kupeli E, Kosar M, Yesilada E, Husnu K, Baser C. A comparative study on the anti-inflammatory, antinociceptive and antipyretic effects of isoquinoline alkaloids from the roots of Turkish Berberis species. Life Sci 2002;72: 645-57.
11. Nam S, Xie J, Perkins A, Ma Y, Yang F, Wu J, et al. Novel synthetic derivatives of the natural product berbamine inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells. Mol Oncol 2012;6: 484-93.
12. Zhao Y, Tan Y,WuG, Liu L, WangY, Luo Y, et al. Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia. Int J Hematol 2011;94: 156-62.
13. WangS, Liu Q, Zhang Y, Liu K, Yu P, Liu K, et al. Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action. Mol Cancer 2009;8:81.
14. Xu R, Dong Q, Yu Y, Zhao X, Gan X, Wu D, et al. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk Res 2006;30: 17-23.
15. Gu Y, Chen T, Meng Z, Gan Y, Xu X, Lou G, et al. CaMKII gamma, a critical regulator ofCML stem/progenitor cells, is a target of the natural product berbamine. Blood 2012;120: 4829-39.
16. Haraguchi N, Ishii H, Mimori K, Tanaka F, Ohkuma M, Kim HM, et al. CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 2010;120: 3326-39.
17. Meng Z, Wang Y, Wang L, Jin W, Liu N, Pan H, et al. FXR regulates liver repair after CCl4-induced toxic injury. Mol Endocrinol 2010;24: 886-97.
18. Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, et al. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 2010;52: 2148-57.
19. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8: 755-68.
20. MaS, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010;7: 694-707.
21. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. Hepatology 2011;53: 160-70.
22. Ozcan L, Wong CC, Li G, Xu T, Pajvani U, Park SK, et al. Calcium signaling through CaMKII regulates hepatic glucose production in fasting and obesity. Cell Metab 2012;15: 739-51.
23. Lisman J, Yasuda R, Raghavachari S. Mechanisms of CaMKII action in long-term potentiation. Nat Rev Neurosci 2012;13: 169-82.
24. Bers DM. CaMKII inhibition in heart failure makes jump to human. Circ Res 2010;107: 1044-6.
25. Bui JD, Calbo S, Hayden-Martinez K, Kane LP, Gardner P, HedrickSM. A role for CaMKII in T cell memory. Cell 2000;100: 457-67.
26. McGargill MA, Sharp LL, Bui JD, Hedrick SM, Calbo S. Active Ca2+/ calmodulin-dependent protein kinase II gamma B impairs positive selection of T cells by modulating TCR signaling. J Immunol 2005;175: 656-64.
27. Nitzki F, Zibat A, Konig S, Wijgerde M, Rosenberger A, Brembeck FH, et al. Tumor stroma-derived Wnt5a induces differentiation of basal cell carcinoma of Ptch-mutant mice via CaMKII. Cancer Res 2010;70: 2739-48.
28. Si J, Mueller L, Collins SJ. CaMKII regulates retinoic acid receptor transcriptional activity and the differentiation of myeloid leukemia cells. J Clin Invest 2007;117: 1412-21.
29. Mamaeva OA, Kim J, Feng G, McDonald JM. Calcium/calmodulindependent kinase II regulates notch-1 signaling in prostate cancer cells. J Cell Biochem 2009;106: 25-32.
30. Si J, Collins SJ. Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation. Cancer Res 2008;68: 3733-42.
31. Liu X, Yao M, Li N, Wang C, Zheng Y, Cao X. CaMKII promotes TLRtriggered proinflammatory cytokine and type I interferon production by directly binding and activating TAK1 and IRF3 in macrophages. Blood 2008;112: 4961-70.
32. Timmins JM, Ozcan L, Seimon TA, Li G, Malagelada C, Backs J, et al. Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways. J Clin Invest 2009;119: 2925-41.
33. He G, Karin M. NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res 2011;21: 159-68.
34. Gomez-Monterrey I, Sala M, Rusciano MR, Monaco S, Maione AS, Iaccarino G, et al. Characterization of a selective CaMKII peptide inhibitor. Eur J Med Chem 2013;62: 425-34.
35. Komiya M, Asano S, Koike N, Koga E, Igarashi J, Nakatani S, et al. Synthesis and structure based optimization of 2-(4-phenoxybenzoyl)- 5-hydroxyindole as a novel CaMKII inhibitor. Bioorg Med Chem 2012;20: 6840-7.